Vaccinia virus, a promising new therapeutic agent for pancreatic cancer
- PMID: 26595180
- PMCID: PMC4976866
- DOI: 10.2217/imt.15.90
Vaccinia virus, a promising new therapeutic agent for pancreatic cancer
Abstract
The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effects by multiple action mechanisms. Vaccinia virus has several inherent features that make it particularly suitable for use as an oncolytic agent. In this review, we will discuss the potential of vaccinia virus in the management of pancreatic cancer in light of our increased understanding of cellular and immunological mechanisms involved in the disease process as well as our extending knowledge in the biology of vaccinia virus.
Keywords: immunotherapy; oncolytic virus; pancreatic cancer; vaccinia virus.
Conflict of interest statement
Financial & competing interests disclosure This project was funded by the Medical Research Council of the UK (MR/MD15696/1), Ministry of Sciences and Technology, China (2013DFG32080) and the UK Charity Pancreatic Cancer Research Fund as well Pancreatic Cancer Research UK. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Figures


Similar articles
-
Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer.Oncol Rep. 2019 Jan;41(1):67-76. doi: 10.3892/or.2018.6817. Epub 2018 Oct 24. Oncol Rep. 2019. PMID: 30365143 Free PMC article.
-
Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.Cancer Lett. 2016 Mar 28;372(2):251-7. doi: 10.1016/j.canlet.2016.01.025. Epub 2016 Jan 21. Cancer Lett. 2016. PMID: 26803055
-
Oncolytic vaccinia virus GLV-1h68 exhibits profound antitumoral activities in cell lines originating from neuroendocrine neoplasms.BMC Cancer. 2020 Jul 6;20(1):628. doi: 10.1186/s12885-020-07121-8. BMC Cancer. 2020. PMID: 32631270 Free PMC article.
-
Immunotherapeutic potential of oncolytic vaccinia virus.Immunol Res. 2011 Aug;50(2-3):286-93. doi: 10.1007/s12026-011-8211-4. Immunol Res. 2011. PMID: 21717084 Review.
-
Advances in oncolytic adenovirus therapy for pancreatic cancer.Cancer Lett. 2018 Oct 10;434:56-69. doi: 10.1016/j.canlet.2018.07.006. Epub 2018 Jul 5. Cancer Lett. 2018. PMID: 29981812 Review.
Cited by
-
Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies.Viruses. 2023 Feb 16;15(2):547. doi: 10.3390/v15020547. Viruses. 2023. PMID: 36851761 Free PMC article. Review.
-
Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.J Transl Med. 2016 Aug 18;14(1):241. doi: 10.1186/s12967-016-1002-x. J Transl Med. 2016. PMID: 27538520 Free PMC article.
-
An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications.Expert Rev Anti Infect Ther. 2021 Mar;19(3):331-344. doi: 10.1080/14787210.2020.1819791. Epub 2020 Sep 15. Expert Rev Anti Infect Ther. 2021. PMID: 32882158 Free PMC article. Review.
-
Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.Int J Mol Sci. 2020 Nov 16;21(22):8627. doi: 10.3390/ijms21228627. Int J Mol Sci. 2020. PMID: 33207653 Free PMC article. Review.
-
Neutralizing monoclonal antibodies improve biodistribution of intravenously administered oncolytic adenovirus in human CD46-transgenic mice.PLoS One. 2025 Jun 25;20(6):e0326857. doi: 10.1371/journal.pone.0326857. eCollection 2025. PLoS One. 2025. PMID: 40561062 Free PMC article.
References
-
- Cancer Research UK. Cancer Research UK; 2014. Pancreatic cancer key stats.
-
- Allison DC, Piantadosi S, Hruban RH, et al. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J. Surg. Oncol. 1998;67(3):151–159. - PubMed
-
- Garcea G, Dennison AR, Pattenden CJ, et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP. 2008;9(2):99–132. - PubMed
-
- Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997;15(6):2403–2413. - PubMed
-
- Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase iii trial of the national cancer institute of canada clinical trials group. J. Clin. Oncol. 2007;25(15):1960–1966. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical